Federal Circuit Affirms Invalidity of Ravgen Prenatal Genetic Testing Patent

In a significant ruling for the molecular diagnostics industry, the U.S. Court of Appeals for the Federal Circuit affirmed the invalidity of Ravgen, Inc.’s patent covering methods for detection of genetic disorders—handing Laboratory Corporation of America Holdings (LabCorp) a decisive appellate victory. Case No. 23-1517, closed on January 29, 2025, after 713 days of litigation, confirms that US7727720B2 does not meet the legal threshold for patentability.

This outcome carries broad implications for prenatal genetic testing patent litigation, an increasingly contested space where diagnostic method patents face mounting validity challenges. For patent attorneys litigating diagnostic method claims, IP professionals managing biotech portfolios, and R&D teams developing next-generation genetic testing platforms, this case offers a critical data point: even commercially deployed, technically sophisticated patents remain vulnerable to invalidity challenges on appeal. The Federal Circuit’s affirmance signals continued judicial scrutiny of genetic testing patents and reinforces the importance of rigorous prosecution strategy at the USPTO.

Case Overview

The Parties

The Patent at Issue

This landmark case involved a patent covering diagnostic method claims directed at identifying chromosomal or genetic abnormalities—technology central to the rapidly growing non-invasive prenatal testing (NIPT) market:

• • US7727720B2 — Methods for detection of genetic disorders, encompassing techniques for analyzing fetal genetic material.

The Verdict & Legal Analysis

Outcome

The Federal Circuit issued a clear disposition: AFFIRMED. The court upheld the finding that US7727720B2 is unpatentable, concluding the invalidity determination from the proceeding below. No damages or injunctive relief are applicable given the invalidity outcome—a finding of unpatentability renders infringement liability moot.

Verdict Cause Analysis

The case was resolved on patentability grounds, specifically through an invalidity/cancellation action. While the full written opinion’s granular reasoning was not included in the provided case data, several analytical inferences are well-supported by the procedural posture:

Invalidity on Appeal: When the Federal Circuit affirms an unpatentability finding, it typically signals that the lower tribunal’s analysis of prior art, obviousness under 35 U.S.C. § 103, or lack of novelty under § 102 was legally sound and factually supported. For diagnostic method patents like Ravgen’s, obviousness challenges frequently invoke combinations of prior art publications in molecular biology and genetic screening.

Claim Construction Implications: Diagnostic method patents are particularly susceptible to validity challenges when claim language is construed broadly, potentially capturing prior art. The Federal Circuit’s affirmance suggests the claim scope, as construed, did not survive validity review.

Patentable Subject Matter Considerations: Given the post-Mayo Collaborative Services v. Prometheus Laboratories (2012) and Association for Molecular Pathology v. Myriad Genetics (2013) landscape, genetic diagnostic method patents face heightened § 101 scrutiny. It is analytically significant that a patent in this space did not survive appeal, though the specific invalidity ground is confirmed only as unpatentability.

Legal Significance

This decision contributes to a growing body of Federal Circuit precedent placing meaningful patentability constraints on genetic testing method claims. For practitioners, it reinforces that:

1. Appellate affirmance of invalidity in diagnostic method cases remains a meaningful risk even for commercially deployed patents.
2. IPR/cancellation proceedings paired with district court litigation continue to be an effective dual-track strategy for patent challengers in the diagnostics space.
3. The Federal Circuit’s consistency in affirming unpatentability findings signals that patent holders must ensure airtight prosecution histories and claim differentiation from prior art.

Case documents may be accessible via PACER under Case No. 23-1517. Patent details for US7727720B2 are publicly available through the USPTO Patent Database.

Industry & Competitive Implications

The LabCorp v. Ravgen outcome has notable implications across the prenatal diagnostics and molecular testing sectors. Ravgen has pursued litigation against multiple major players in the NIPT market, and an appellate invalidity affirmance on a core patent weakens its broader assertion campaign.

For LabCorp and similarly situated diagnostics companies, this outcome validates investment in aggressive patent validity challenges. It also reduces licensing pressure from this specific patent, potentially affecting royalty negotiations across Ravgen’s litigation portfolio.

For the NIPT industry broadly, the ruling contributes to a more open competitive environment for genetic disorder detection methods, potentially accelerating innovation by reducing the risk of infringement exposure tied to US7727720B2. Companies developing or commercializing prenatal testing platforms should update their FTO assessments in light of this decision.

From a licensing and settlement perspective, an invalidity affirmance from the Federal Circuit materially reduces a patent holder’s leverage in ongoing or future licensing negotiations involving the invalidated patent. Entities that previously settled with Ravgen on terms reflecting the patent’s assumed validity may find that outcome commercially instructive for future IP valuation exercises.

Explore related Federal Circuit decisions in diagnostic patent litigation via the Federal Circuit’s official opinions database.

Frequently Asked Questions

What patent was at issue in LabCorp v. Ravgen, Case No. 23-1517?

The case concerned US7727720B2 (Application No. US11/212812), covering methods for detection of genetic disorders.

What was the Federal Circuit’s ruling?

The court affirmed the lower tribunal’s finding, concluding the patent is unpatentable. The case closed January 29, 2025.

How does this affect prenatal genetic testing patent litigation?

The ruling weakens Ravgen’s patent assertion position in the NIPT space and signals continued Federal Circuit scrutiny of diagnostic method patent validity.